These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 38416033)

  • 1. Effect of Spironolactone on Kidney Function in Kidney Transplant Recipients (the SPIREN trial): A Randomized Placebo-Controlled Clinical Trial.
    Mortensen LA; Jespersen B; Helligsoe ASL; Tougaard B; Cibulskyte-Ninkovic D; Egfjord M; Boesby L; Marcussen N; Madsen K; Jensen BL; Petersen I; Bistrup C; Thiesson HC
    Clin J Am Soc Nephrol; 2024 Jun; 19(6):755-766. PubMed ID: 38416033
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effect of spironolactone on calcineurin inhibitor induced nephrotoxicity: a multicenter randomized, double-blind, clinical trial (the SPIREN trial).
    Mortensen LA; Thiesson HC; Tougaard B; Egfjord M; Fischer ASL; Bistrup C
    BMC Nephrol; 2018 May; 19(1):105. PubMed ID: 29724188
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Spironolactone reduces oxidative stress in living donor kidney transplantation: a randomized controlled trial.
    Morales-Buenrostro LE; Ortega-Trejo JA; Pérez-Villalva R; Marino LA; González-Bobadilla Y; Juárez H; Zamora-Mejía FM; González N; Espinoza R; Barrera-Chimal J; Bobadilla NA
    Am J Physiol Renal Physiol; 2019 Sep; 317(3):F519-F528. PubMed ID: 31241992
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of spironolactone for 1 yr on endothelial function and vascular inflammation biomarkers in renal transplant recipients.
    Mortensen LA; Bistrup C; Stubbe J; Carlström M; Checa A; Wheelock CE; Palarasah Y; Bladbjerg EM; Thiesson HC; Jensen BL
    Am J Physiol Renal Physiol; 2019 Sep; 317(3):F529-F539. PubMed ID: 31166706
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Randomized Controlled Trial of Mineralocorticoid Receptor Blockade in Children with Chronic Kidney Allograft Nephropathy.
    Medeiros M; Velásquez-Jones L; Hernández AM; Ramón-García G; Valverde S; Fuentes Y; Vargas A; Patiño M; Pérez-Villalva R; Ortega-Trejo JA; Barrera-Chimal J; Bobadilla NA
    Clin J Am Soc Nephrol; 2017 Aug; 12(8):1291-1300. PubMed ID: 28536123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of Spironolactone and Chlorthalidone on Cardiovascular Structure and Function in Chronic Kidney Disease: A Randomized, Open-Label Trial.
    Edwards NC; Price AM; Mehta S; Hiemstra TF; Kaur A; Greasley PJ; Webb DJ; Dhaun N; MacIntyre IM; Farrah T; Melville V; Herrey AS; Slinn G; Wale R; Ives N; Wheeler DC; Wilkinson I; Steeds RP; Ferro CJ; Townend JN
    Clin J Am Soc Nephrol; 2021 Oct; 16(10):1491-1501. PubMed ID: 34462286
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mineralocorticoid receptor blockade with spironolactone has no direct effect on plasma IL-17A and injury markers in urine from kidney transplant patients.
    Thangaraj SS; Thiesson HC; Svenningsen P; Stubbe J; Palarasah Y; Bistrup C; Jensen BL; Mortensen LA
    Am J Physiol Renal Physiol; 2022 Feb; 322(2):F138-F149. PubMed ID: 34894724
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Management of resistant hypertension: aldosterone antagonists or intensification of diuretic therapy?
    Verdalles U; García de Vinuesa S; Goicoechea M; Macías N; Santos A; Perez de Jose A; Verde E; Yuste C; Luño J
    Nephrology (Carlton); 2015 Aug; 20(8):567-71. PubMed ID: 25818266
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early detection of diabetic kidney disease by urinary proteomics and subsequent intervention with spironolactone to delay progression (PRIORITY): a prospective observational study and embedded randomised placebo-controlled trial.
    Tofte N; Lindhardt M; Adamova K; Bakker SJL; Beige J; Beulens JWJ; Birkenfeld AL; Currie G; Delles C; Dimos I; Francová L; Frimodt-Møller M; Girman P; Göke R; Havrdova T; Heerspink HJL; Kooy A; Laverman GD; Mischak H; Navis G; Nijpels G; Noutsou M; Ortiz A; Parvanova A; Persson F; Petrie JR; Ruggenenti PL; Rutters F; Rychlík I; Siwy J; Spasovski G; Speeckaert M; Trillini M; Zürbig P; von der Leyen H; Rossing P;
    Lancet Diabetes Endocrinol; 2020 Apr; 8(4):301-312. PubMed ID: 32135136
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Renoprotective effects of mineralocorticoid receptor blockers in patients with proteinuric kidney diseases.
    Morales E; Millet VG; Rojas-Rivera J; Huerta A; Gutiérrez E; Gutiérrez-Solís E; Egido J; Praga M
    Nephrol Dial Transplant; 2013 Feb; 28(2):405-12. PubMed ID: 23222416
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sex Differences in Renal Outcomes After Medical Treatment for Bilateral Primary Aldosteronism.
    Nakamaru R; Yamamoto K; Akasaka H; Rakugi H; Kurihara I; Yoneda T; Ichijo T; Katabami T; Tsuiki M; Wada N; Yamada T; Kobayashi H; Tamura K; Ogawa Y; Kawashima J; Inagaki N; Fujita M; Oki K; Kamemura K; Tanabe A; Naruse M;
    Hypertension; 2021 Feb; 77(2):537-545. PubMed ID: 33356395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spironolactone in Patients With Heart Failure, Preserved Ejection Fraction, and Worsening Renal Function.
    Beldhuis IE; Myhre PL; Bristow M; Claggett B; Damman K; Fang JC; Fleg JL; McKinlay S; Lewis EF; O'Meara E; Pitt B; Shah SJ; Vardeny O; Voors AA; Pfeffer MA; Solomon SD; Desai AS
    J Am Coll Cardiol; 2021 Mar; 77(9):1211-1221. PubMed ID: 33663739
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mineralocorticoid receptor blockade reduced oxidative stress in renal transplant recipients: a double-blind, randomized pilot study.
    Ojeda-Cervantes M; Barrera-Chimal J; Alberú J; Pérez-Villalva R; Morales-Buenrostro LE; Bobadilla NA
    Am J Nephrol; 2013; 37(5):481-90. PubMed ID: 23635604
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-albuminuric effects of spironolactone in patients with type 2 diabetic nephropathy: a multicenter, randomized clinical trial.
    Kato S; Maruyama S; Makino H; Wada J; Ogawa D; Uzu T; Araki H; Koya D; Kanasaki K; Oiso Y; Goto M; Nishiyama A; Kobori H; Imai E; Ando M; Matsuo S
    Clin Exp Nephrol; 2015 Dec; 19(6):1098-106. PubMed ID: 25795029
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long-term effects of aldosterone blockade in resistant hypertension associated with chronic kidney disease.
    Pisoni R; Acelajado MC; Cartmill FR; Dudenbostel T; Dell'Italia LJ; Cofield SS; Oparil S; Calhoun DA
    J Hum Hypertens; 2012 Aug; 26(8):502-6. PubMed ID: 21677673
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The safety and tolerability of spironolactone in patients with mild to moderate chronic kidney disease.
    Edwards NC; Steeds RP; Chue CD; Stewart PM; Ferro CJ; Townend JN
    Br J Clin Pharmacol; 2012 Mar; 73(3):447-54. PubMed ID: 21950312
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Spironolactone to prevent cardiovascular events in early-stage chronic kidney disease (STOP-CKD): study protocol for a randomized controlled pilot trial.
    Ng KP; Jain P; Heer G; Redman V; Chagoury OL; Dowswell G; Greenfield S; Freemantle N; Townend JN; Gill PS; McManus RJ; Ferro CJ
    Trials; 2014 May; 15():158. PubMed ID: 24886272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mineralocorticoid Receptor Antagonists for Hypertension Management in Advanced Chronic Kidney Disease: BLOCK-CKD Trial.
    Bakris G; Yang YF; Pitt B
    Hypertension; 2020 Jul; 76(1):144-149. PubMed ID: 32520623
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term effects of spironolactone on proteinuria and kidney function in patients with chronic kidney disease.
    Bianchi S; Bigazzi R; Campese VM
    Kidney Int; 2006 Dec; 70(12):2116-23. PubMed ID: 17035949
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mineralocorticoid Receptor Antagonist Use and Hard Renal Outcomes in Real-World Patients With Chronic Kidney Disease.
    Oka T; Sakaguchi Y; Hattori K; Asahina Y; Kajimoto S; Doi Y; Kaimori JY; Isaka Y
    Hypertension; 2022 Mar; 79(3):679-689. PubMed ID: 35026955
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.